SCHEMBL2172085

SCHEMBL2172085

CNC(=O)Oc1ccc(N2CCCC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.50
KMT2A Q03164 6/20 0.50
ALDH1A1 P00352 6/20 0.50
GAA P10253 3/20 0.50
KDM4E B2RXH2 3/20 0.50
RAB9A P51151 2/20 0.50
MEN1 O00255 1/20 0.50
NR4A1 P22736 1/20 0.50
MCL1 Q07820 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
GFER P55789 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
ALOX15 P16050 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TP53 P04637 2/20 0.48
USP2 O75604 2/20 0.48
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172968 0.81 MAPT (0.56) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL4812656 0.81 GLA (0.57) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL12893245 0.80 ALDH1A1 (0.51) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL15535616 0.79 CYP1A2 (0.54) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL8542788 0.77 ALDH1A1 (0.47) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL2175054 0.77 RAB9A (0.63) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL2176595 0.76 ALDH1A1 (0.76) MAPTKMT2AALDH1A1RAB9AMEN1
SCHEMBL28096400 0.76 ALDH1A1 (0.50) MAPTKMT2AALDH1A1GAAKDM4E
Hydrochloric Acid SCHEMBL23040410 0.75 MAPT (0.59) MAPTKMT2AALDH1A1GAAKDM4E
SCHEMBL5648923 0.75 ALDH1A1 (0.79) MAPTKMT2AALDH1A1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 US disclosed
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases LNCYTE CORPORATION (US) 2008-07-10 US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 MAPT 2590/4885KMT2A 1912/4885ALDH1A1 673/4885
US-20080167288-A1 Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases MMP25, MMP9, MMP24 MAPT 3223/4885KMT2A 2227/4885ALDH1A1 415/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 MAPT 2732/4885KMT2A 1880/4885ALDH1A1 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.